Shamburg News · 8-K filed Oct 29, 2026, 4:05 PM EDT

Enanta Pharmaceuticals' EU patent suit against Pfizer over Paxlovid dismissed after UPC invalidity ruling

ENTA · ENANTA PHARMACEUTICALS INC

  • Other event
  • Materiality: medium

Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court against Pfizer Inc. and certain subsidiaries concerning European Patent No. EP 4 051 265 and Paxlovid sales in the 18 participating EU member states. Pfizer counterclaimed for revocation of the patent, and a hearing was held on September 29, 2026. On October 29, 2026, the UPC decided that the '265 Patent is invalid and that the infringement action was unfounded.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001193125-26-437774.

Written from the filing by Shamburg Markets. Figures are as reported by the company.